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amining predictors of medication class prescribed. RESULTS: There were 4,916
individuals in the study (1,788 in DA cohort, 646 in MAO-B, and 2,482 in LD). Results
of the logistic regression revealed that older patients were significantly less likely
to receive DA (OR0.977; 95% CI 0.966-0.988) or a MAO-B (OR0.968; 95% CI0.954-
0.983), compared to LD. Compared to LD cohort, patients who receive a MAO-B were
significantly less likely to be diagnosed with pre-period depression (OR0.540; 95%
CI 0.310-0.940) and patients who received a MAO-B or DA were significantly less
likely to be diagnosed with psychoses (MAO-B - OR0.220; 95% CI 0.105-0.459: DA –
OR0.732; 95% CI 0.542-0.989). Furthermore, results revealed that patients diag-
nosed by a neurologist were significantly more likely to receive a DA (OR1.651;
95% CI 1.353-2.014) or a MAO-B (OR1.607; 95% CI 1.193 – 2.165), compared to LD.
Region of residence and health plan membership were also found to predict initial
medication class. CONCLUSIONS: These analyses indicate that patient character-
istics, health status, diagnosing physician and access disparities all impact initial
therapeutic class of medication prescribed for patients with PD.
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OBJECTIVES: During 2007-2011 Multiple Sclerosis (MS) was the only category that
experienced triple digit growth in sales, leading to doubling of their sales from $3.4
billion in 2007 to $7 billion in 2011. This has led to change in payer coverage and
utilization of branded MS products. This study was undertaken to understand
current trends in sales, access and utilization management for MS products in the
United States. METHODS: Sales data for MS branded products was analyzed using
IMS Health 2007-2011 data. Access and utilization management trends were ana-
lyzed using preferred drug list and coverage policies of top US health plans. Primary
discussions were conducted with pharmacy and medical directors to understand
new trends in coverage of MS products. RESULTS: More than half (approximately
59%) of the branded MS products are covered by health plans as non-preferred
products or at Tier 3/4 . Significant majority (84%) of these products were covered
with prior authorization or pre-certification criteria. Quantity limits were used by
34% of the plans. Use of step therapy or progression prescription is not currently
common and was found in only 5% of the plans. In this sample (n37), only one
plan ( 5%) had formulary exclusion for an MS product. Payer designated specialty
pharmacies are increasingly being used by various health plans. Compared to 2007,
payer coverage of MS products shows significant increase in use of PA (40% in 2007
versus 84% in 2012). Payers express high concern for rapidly growing MS category
and report use of more utilization management approaches to control spending.
CONCLUSIONS: MS products are facing more aggressive utilization management.
Patient access for new MS therapies could be limited due to non-preferred status,
high co-pay or strict PA criteria.
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OBJECTIVES: To map the health care utilization of multiple sclerosis (MS) patients
incl. MS-specific drug therapy in the ambulatory setting of the Statutory Health
Insurance (SHI) system in Bavaria/Germany. METHODS: Pseudonymised adminis-
trative claims data of the SHI-accredited physicians in Bavaria/Germany (April 2005
– December 2009) were used. Patients with at least one MS diagnosis (ICD-10 G35)
documented by a neurologist or psychiatrist or at least one disease modifying drug
(DMD) prescription (interferon beta-1(a/b), glatirameracetat, or natalizumab). All
cases of outpatient medical services with an MS diagnosis were considered. Anal-
ysis of MS-associated drug therapy included DMD, drugs used for symptomatic
relief and systemic corticosteroids for relapse therapy. Persistence (duration of
continuous prescription) and medication possession ratio (MPR; percentage of days
covered by medication) were calculated for DMD. RESULTS: The annual number of
MS patients ranged from n12.800 (2005) to n18.200 (2009). The proportion of
patients with at least one DMD prescription (interferon beta, glatirameracetat, na-
talizumab, azathioprin) increased from 46% (2005) to 51% (2009). The average per-
sistence for these drugs (excl. natalizumab) varied between 12 months (glatiram-
eracetat) and 14 months (interferons). The median MPR varied between 0,69
(natalizumab) and 0,84 (interferon beta 1-a) in the first year following the index
prescription. Mostly, these drugs were prescribed by neurologists. In total, 10,060
patients receiving systemic corticosteroids for the therapy of relapse were identi-
fied between 2005 and 2009. The average number of such therapies per year and
patient was about 1.5. The percentage of patients with relevant MRI scans (neuro-
cranium / spinal cord) was substantial higher in patients with relapse therapies
compared with patients without such therapy. CONCLUSIONS: The analysis indi-
cated (1) an increase of disease prevalence but also of patients supplied with DMD
between 2005 and 2009 and (2) the importance of neurologists within the MS treat-
ment.
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OBJECTIVES: To identify and explore how reimbursement decisions for natali-
zumab, a treatment for multiple sclerosis (MS), were overturned from an initial
rejection to a recommendation. METHODS: This analysis was conducted in con-
juntion with a wider review of the global reimbursement landscape for MS thera-
pies. We reviewed reimbursement decisions or recommendations from global
payer decision-making agencies, including any decisions where an initial rejection
was overturned. We reviewed the agency rationale for both the original and sub-
sequent decisions, and how the manufacturer influenced the decision reversal.
RESULTS: Since 2006, 17 payer decisions for natalizumab were identified (six rec-
ommendations, eight restricted recommendations and three rejections). The three
rejected decisions were later overturned by the manufacturer submitting further
evidence. To PBAC this involved re-defining the indirect comparison to consider
the heterogeneity in the trials included. To SMC and CADTH post-hoc analysis was
submitted for the specific subgroup of rapidly evolving severe relapsing remitting
MS. For CADTH a 15% price discount was agreed in addition. Across all agencies
clinical need was an important factor. CONCLUSIONS: By emphasising unmet
needs, submitting further evidence in defined subgroups and ensuring indirect
comparisons are methodologically sound, it has been possible to overturn initial
negative decisions by payer agencies to restricted recommendations in define sub-
group. Identification of the optimum treatable population has proved pivotal in the
reversal of fortune.
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OBJECTIVES: There is conflicting evidence in published literature regarding the
association between montelukast and neuropsychiatric disturbances. We sought
to determine if the use of montelukast was associated with neuropsychiatric dis-
turbances in children with Asthma.METHODS:A 10% sample of the LifeLink health
plan claims data was used to identify subjects less than 18 years of age with a
primary diagnosis of asthma between Jan 1, 1998 and Dec 31, 2009. Multiple case
definitions for neuropsychiatric disturbances were formulated ranging from nar-
row to broad measures based on the diagnoses of neuropsychiatric related disor-
ders or use of a psychotropic medication. We used a nested case control design and
each case was matched to 3 controls on age, gender and geographic region and
controls were assigned an index date based on the matched case. Exposure to
montelukast was measured as any exposure during the year, recency of exposure,
cumulative duration of exposure and cumulative dose of exposure during the 30
days and 365 days prior to the outcome. Conditional logistic regression was used to
estimate the unadjusted and the adjusted odds ratios after controlling for
confounders. RESULTS: Using the broadest definition for neuropsychiatric distur-
bances, 1,920 cases and 5,760 matching controls were identified. Cases were more
likely to be diagnosed with epilepsy, diabetes, cancer and hypothyroidism, and
were more likely to use inhaled corticosteroids, long-acting beta2-agonists, sys-
temic corticosteroids and metoclopramide. Subjects exposed to montelukast dur-
ing the year had an unadjusted OR of 1.085 (CI 0.962 – 1.223) and an adjusted OR of
1.032 (CI 0.909 – 1.172) for experiencing a neuropsychiatric disturbance. None of the
other montelukast exposure measures showed a positive association except a cu-
mulative dose of exposure between 351mg and 900mg (OR1.308; CI: 1.082 – 1.581).
CONCLUSIONS: Preliminary results do not suggest a consistent positive associa-
tion between montelukast and neuropsychiatric disturbances.
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OBJECTIVES: COPD is an important cause of morbidity and mortality. Statistics
Korea presented in 2009 the mortality of COPD was 9.4 per one hundred thousand
marking the disease as one of the 10 major death causes in Korea. This study was
performed to investigate epidemiologic data especially incidence and risk factors
associated with COPD exacerbations in Korea.METHODS: A retrospective observa-
tional study was carried out on 1,112 COPD patients from 47 medical centers
throughout Korea. The data collection was performed at enrollment and a past year
from the enrollment. The COPD patients were defined by GOLD criteria 2010. Also
we investigated demographic characteristics, COPD exacerbation, Lung function
Test, Comorbidity, COPD assessment test (CAT), and COPD medication. RESULTS:
Among 1,112 patients, more than half of the respondents were more than 70 years
old, 91% (n1,011) were male, mean BMI was 22.2 (SD 3.3) kg/m2, mean COPD
duration was 5.8 years, and 55.5% (n616) were classified as chronic bronchitis. The
occurrence of exacerbation was 35.4% (n394), the mean frequency of exacerba-
tion in past year was 0.67 (SD1.28), and decrease of FEV1/FVC results align with
GOLD stage was statistically significant (p0.0001). The most frequently reported
comorbidities were hypertension (36.0%, n400) and bronchial asthma (16.6%,
n185). Mean CAT sum score was 16.8 (SD 8.3). The most frequently used COPD
medication was long-acting muscarinic antagonist (47.9%). Multivariate logistic
regression results show the effect on exacerbation in the subjects who had only
pulmonary emphysema was 0.7 times than the subjects who had only chronic
bronchitis (95%CI [0.49-0.96], p-value0.001), and subjects with history of pneumo-
nia were 11.1 times higher than in the subjects without history of pneumonia (95%
CI [6.89-17.87], p-value0.0001). CONCLUSIONS: Our results suggested that the
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COPD phenotypes and history of pneumonia can impact on exacerbation of COPD
in Korea. We need to investigate further prospective studies to reach the concrete
conclusion.
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OBJECTIVES: Omalizumab has been shown to decrease the risk of hospitalisation
or emergency visits in patients with uncontrolled severe allergic asthma as com-
pared to placebo. This longitudinal study observed the conditions under which
omalizumab is prescribed in real-life settings; and assessed whether its use, as an
add-on therapy alongside standard treatments, decreases the risk of severe asth-
matic exacerbations. METHODS: A cohort of adult patients with uncontrolled se-
vere asthma despite optimal treatment with inhaled and oral corticosteroids and a
long-acting beta2-agonist, but no treatment with omalizumab upon entry, was
assembled. Risk of hospitalisation and/or emergency room visits for asthma exac-
erbation was assessed using the Andersen-Gill extension of the Cox model for
repeated events controlling for age, gender, smoking history, body mass index,
gastro-oesophageal reflux, allergic status, allergic rhinitis, treatment, and hospi-
talisation or emergency room visits for asthma in the 2 months prior to omali-
zumab treatment. RESULTS: Overall, 163 physicians recruited 767 patients, of
whom 374 took omalizumab at least once (mean observation period: 20.4 months).
Omalizumab use was associated with an adjusted relative risk of hospitalisation
and/or emergency room visits for asthma of 0.57 (95% confidence interval: 0.43-
0.78). In omalizumab users, the adjusted relative risk of hospitalisation and/or
emergency room visits for asthma during omalizumab treatment versus non-treat-
ment periods was 0.40 (95% confidence interval: 0.28-0.58). CONCLUSIONS:Add-on
omalizumab significantly decreases the risk of hospitalisation/emergency room
visits in patients with uncontrolled severe asthma in the real-life practice.
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COMPARATIVE EFFICACY OF ACLIDINIUM BROMIDE 400 MCG BID VERSUS
TIOTROPIUM 18 MCG AND 5 MCG QD AS MAINTENANCE BRONCHODILATOR
TREATMENT TO RELIEVE SYMPTOMS IN ADULT PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD): A NETWORK META-ANALYSIS
Karabis A1, Lindner L2, Mocarski M3, Bouwmeester W1, Karakurum C2, Prior M2, Bergman
G1
1MAPI Consultancy, Houten, The Netherlands, 2Almirall S.A., Barcelona, Spain, 3Forest Research
Institute, Jersey City, NJ, USA
OBJECTIVES: To estimate the relative efficacy of a new long-acting muscarinic
antagonist (LAMA), aclidinium bromide 400 g BID (AB400), to tiotropium bromide
18 g (TIO18) and 5 g (TIO5) QD in patients with COPD. METHODS: A systematic
literature search using a predefined strategy in MEDLINE©, EMBASE© and the Co-
chrane Library identified 21 unique placebo-controlled RCTs: TIO18 (16 trials), TIO5
(3 trials) and AB400 (2 trials). Outcomes were change from baseline (CFB) in lung
function (trough FEV1), disease-specific health status by St. George’s Respiratory
Questionnaire (SGRQ) total score, and breathlessness by Transition Dyspnea Index
(TDI) focal score, at 12 and 24 weeks. All trials were analysed simultaneously using
a Bayesian network meta-analysis and relative treatment effects between all reg-
imens were obtained. Meta-regression techniques were included to investigate
dissimilarities in study design and patient characteristics across trials. RESULTS:
In line with the pivotal trials, AB400 was shown to be more efficacious than placebo
on all evaluated endpoints. AB400 showed comparable but numerically greater
improvements at 12 weeks compared to TIO18 in trough FEV1 [difference in CFB
(95% Credible Interval) 0.001L (-0.03,0.03)], SGRQ total score [-0.85 (-3.41,1.75)] and
TDI focal score [0.06 (-0.41,0.52)]. Similar but numerically greater differences were
also seen for AB400 versus TIO18 at 24 weeks in trough FEV1 [0.02L (-0.02,0.08)],
SGRQ total score [-1.84 (-4.21,0.51)] and TDI focal score [0.10 (-0.53,0.73)]. Addition-
ally, AB400 showed similar improvements on these same endpoints versus TIO5
(where data was available). Meta-regression analyses, correcting for differences in
treatment patterns (concurrent ICS, LABA treatment) and COPD severity (baseline
FEV1 percent predicted) across the trials, showed comparable findings as the base
case analysis. CONCLUSIONS: This meta-analysis suggests that maintenance
treatment with aclidinium 400 g BID results in comparable improvements in lung
function, health status, and breathlessness as tiotropium 18 g and 5 g QD in
COPD patients.
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OBJECTIVES: To evaluate the relative efficacy of indacaterol 150g  tiotropium
18g (IND/TIO) versus triple therapies (i.e. tiotropium plus a fixed-dose combina-
tion [FDC] of a long-acting beta2-agonist [LABA] and inhaled corticosteroid [ICS]), a
LABA/ICS FDC alone, and monotherapies, including indacaterol, tiotropium, acli-
dinium, salmeterol, formoterol, and placebo in patients with moderate to severe
chronic obstructive pulmonary disease (COPD) in terms of trough FEV1 at 12 weeks.
METHODS: Several of the treatments to be compared include ICS as part of the
study treatment. Therefore the evidence base was restricted to RCTs not allowing
for concomitant ICS use (for Novartis studies subgroup data for non-ICS users were
included). For this population 23 RCTs were identified based on a systematic liter-
ature review, which were analysed simultaneously using a Bayesian network
meta-analysis. Treatment-by-covariate interactions were included for the propor-
tion of current-smokers to improve similarity of the trials. RESULTS: IND/TIO re-
sulted in a higher change from baseline (CFB) in FEV1 by 0.24L (95%CrI: 0.20, 0.27)
versus placebo at 12 weeks. IND/TIO is likely to be favourable versus salmeterol/
fluticasone 50/500g tiotropium 18g [difference 0.03L (95%CrI: -0.01, 0.07); prob-
ability better: 94%] and comparable to formoterol/budesonide 9/320g  tiotro-
pium 18g [difference 0.02L (95%CrI: -0.02, 0.06); probability better: 80%]. IND/TIO
has a larger CFB than the FDCs alone with an advantage of 0.07L (95%CrI: 0.03, 0.12)
to 0.09L (95%CrI: 0.04, 0.15). IND/TIO also has a higher CFB than the monotherapies
assessed. Out of the 13 regimens evaluated, there is a 77% probability that IND/TIO
is the most efficacious treatment in terms of CFB in FEV1. Results were not sensitive
to adjustment for smokers or to the exclusion of RCTs with concomitant anticho-
linergics or an exacerbation history. CONCLUSIONS: IND/TIO is expected be com-
parable to triple therapies and more efficacious than FDCs and monotherapies in
terms of FEV1 at 12 weeks.
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OBJECTIVES: To compare the prevalence of selected medical conditions in Russia
as estimated using the National Health and Wellness Survey (NHWS) with those
from the medical literature. METHODS: This study used data from the 2011 Russia
NHWS, a cross-sectional survey administered to 10,039 adults living in large Rus-
sian cities recruited through both online and offline methods. All data were self-
reported. Weighted prevalence was estimated through self-report and validated
scales embedded in the questionnaire. Conditions included depression, restless
legs syndrome, and sleep difficulties, among others. Gender differences were also
assessed. NHWS estimates were compared with prevalence estimates taken from
published studies. RESULTS: Twelve-month prevalence estimates of depression
according to self-report were 20% in men and 25% in women, and depression of
moderate or greater severity was identified through Patient Health Questionnaire
(PHQ-9) in 17% of men and 21% of women, both slightly higher than the approxi-
mately 10% and 20% estimates of clinically significant depression in men and
women, respectively, reported by Akarachkova and Vershinina (2010). In NHWS,
restless leg syndrome was reported by 6% and 10% of men and women respectively,
and found to affect 8% of men and 10% of women by Romanova (2008). Difficulty
falling asleep was estimated at 25% of men and 32% of women in NHWS, and 30%
of men and 28% of women (Romanova, 2008). Prevalence for all conditions among
urban Russian adults was much lower across conditions when limited to patients
reporting a diagnosis confirmed by a doctor. CONCLUSIONS: Prevalence estimates
and gender differences calculated from NHWS Russia data were generally similar
to those taken from previous literature, providing initial evidence for its use in
estimating prevalence of disease in urban Russia. Reports of experiencing a condi-
tion were much more common than reports of confirmed diagnosis, suggesting
substantial unmet medical need.
PRS7
PATTERNS OF INTRANASAL CORTICOSTEROID USE AMONG INDIVIDUALS
DIAGNOSED WITH ALLERGIC RHINITIS: EVIDENCE FROM A LARGE CLAIMS
DATABASE
Lage MJ1, Gross GN2, Buck PO3, Lepore MS3
1HealthMetrics Outcomes Research, Delray Beach, FL, USA, 2Dallas Allergy and Asthma Center,
Dallas, TX, USA, 3Teva Pharmaceuticals, Frazer, PA, USA
OBJECTIVES: Examine patient characteristics and patterns of intranasal corticoste-
roid (INS) use among individuals diagnosed with allergic rhinitis (AR) from a large,
US retrospective claims database.METHODS: The i3 Invision™ Data Mart was used
from January 1, 2006 through December 31, 2010. AR patients aged 12 years were
included if they received an aqueous INS formulation (with first such date identi-
fied as index date) and had continuous insurance coverage from 6 months before
through 24 months after index date. Patients diagnosed with chronic rhinitis or
nasal polyps were excluded. Data are descriptive in nature. RESULTS: The sample
consisted of 163,473 individuals with a mean age of 41 years (SD15), 59% female,
and 55% residing in the southern US. Patients were most commonly prescribed
generic fluticasone propionate (44%), mometasone (34%), or triamcinolone (10%)
and had a high degree of related comorbidities, including sinusitis (40%), asthma
(15%), and otitis media (12%). Treatment patterns during the first year after index
date: a mean of 2.1 INS prescriptions were filled (median1.0; SD1.8), adherence
as measured by the medication possession ratio averaged 18% (median8; SD16),
and persistence averaged 135 days (median30; SD134). Furthermore, 7% of pa-
tients switched INS products during their first year of use, with 5% of patients who
initially received generic INS switching to a branded INS product. CONCLUSIONS:
Although INSs are considered the gold standard for symptomatic treatment of AR,
this examination of a large US claims database demonstrated that patients with AR
who filled at least 1 aqueous INS prescription generally did not use their INS for an
extended period of time.
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